A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel plus sorafenib in women with node positive or high-risk breast cancer.

被引：0
|
作者：
Spigel, D. R.
Molthrop, D.
Peacock, N.
Kommor, M.
Markus, T.
Vazquez, E.
Greco, F. A.
Burris, H. A.
Hainsworth, J. D.
Yardley, D. A.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Tennessee Oncol PLLC, Nashville, TN USA
[3] Florida Hosp Canc Inst, Orlando, FL USA
[4] Consultants Blood Disorders & Canc, Louisville, KY USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190S / 190S
页数：1
相关论文
共 50 条
  • [21] Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
    Mamounas, EP
    Bryant, J
    Leinbersky, B
    Fehrenbacher, L
    Sedlacek, SM
    Fisher, B
    Wickerham, DL
    Yothers, G
    Soran, A
    Wolmark, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3686 - 3696
  • [22] Pilot study of dose dense doxorubicin plus cyclophosphamide followed by ABI-007 in patients with early stage breast cancer.
    Robert, N
    Ambro, S
    Krekow, L
    Stokoe, C
    Bhar, P
    Hawkins, MJ
    O'Shaughnessy, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S109 - S109
  • [23] Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study
    Cardoso, F
    Ferreira, AF
    Crown, J
    Dolci, S
    Paesmans, M
    Riva, A
    Di Leo, A
    Piccart, MJ
    [J]. ANTICANCER RESEARCH, 2001, 21 (1B) : 789 - 795
  • [24] Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer
    Cetnar, Jeremy P.
    Malkowicz, Bruce
    Palmer, Steven C.
    Wein, Alan J.
    Vaughn, David J.
    [J]. UROLOGY, 2008, 71 (05) : 942 - 946
  • [25] Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting
    Burtness, B
    Windsor, S
    Holston, B
    DiStasio, S
    Staugaard-Hahn, C
    Abrantes, J
    Kneuper-Hall, R
    Farber, L
    Orell, J
    Bober-Sorcinelli, K
    Haffty, BG
    Reiss, M
    [J]. CANCER JOURNAL, 1999, 5 (04): : 224 - 229
  • [26] Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel
    Rojo, Federico
    Lluch, Ana
    Ruiz, Amparo
    Ruiz-Borrego, Manuel
    Barnadas, Agusti
    Calvo, Lourdes
    Gonzalez, Sonia
    Margeli, Mireia
    Rodriguez-Lescure, Alvaro
    Anton, Antonio
    Angel Segui, Miguel
    Munoz-Mateu, Montserrat
    Dorca, Joan
    Manuel Lopez-Vega, Jose
    Jara-Sanchez, Carlos
    Martin, Nuria
    Casas, Maribel
    Maria Carrasco, Eva
    Caballero, Rosalia
    Martin, Miguel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] A phase III adjuvant trial of sequenced EC plus filgrastim plus epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)
    Burnell, M. J.
    Levine, M. N.
    Chapman, J. A.
    Bramwell, V.
    Vandenberg, T.
    Chalchal, H. I.
    Albain, K.
    Perez, E.
    Rugo, H.
    Pritchard, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
    Gil-Gil, Miguel J.
    Bellet, M.
    Morales, S.
    Ojeda, B.
    Manso, L.
    Mesia, C.
    Garcia-Martinez, E.
    Martinez-Janez, N.
    Mele, M.
    Llombart, A.
    Pernas, S.
    Villagrasa, P.
    Blasco, C.
    Baselga, J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) : 597 - 606
  • [29] Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
    Miguel J. Gil-Gil
    M. Bellet
    S. Morales
    B. Ojeda
    L. Manso
    C. Mesia
    E. Garcia-Martínez
    N. Martinez-Jáñez
    M. Melé
    A. Llombart
    S. Pernas
    P. Villagrasa
    C. Blasco
    J. Baselga
    [J]. Breast Cancer Research and Treatment, 2015, 151 : 597 - 606
  • [30] A phase II study of adjuvant chemotherapy with sequential doxorubicin-cyclophosphamide (AC) and docetaxel followed by radiotherapy in patients with high-risk early breast cancer. A trial of the Pakistan Cancer Research Group
    Khan, Shaharyar
    Shah, Ijaz H.
    Shahid, Abubaker
    Hafeez, Muhammed
    Perveen, Shaheena
    Javed, Abrar A.
    Masood, Ahmed I.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 66 - 67
12345